Korsana Biosciences, Inc. (KRSA) stock
KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30493% above fair value
$32.50−0.18 (-0.55%)
Close on Nov 17, 2026Market cap $152.14MP/E –Yield –
Korsana Biosciences cash
Cash and short-term investments held at the end of each period.
Korsana Biosciences's cash was $1.39M at Jun 30, 2026. For fiscal 2025 it was $3.24M, up 0.2% from the year before. The highest annual figure on record is $102.62M in fiscal 2019.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.24M | +0.2% |
| FY2024 | Dec 31, 2024 | $3.23M | -57.3% |
| FY2023 | Dec 31, 2023 | $7.57M | -43.4% |
| FY2022 | Dec 31, 2022 | $13.38M | -75.2% |
| FY2021 | Dec 31, 2021 | $53.96M | -7.3% |
| FY2020 | Dec 31, 2020 | $58.23M | -43.3% |
| FY2019 | Dec 31, 2019 | $102.62M | – |
| FY2018 | Dec 31, 2018 | $0 | – |
| FY2017 | Dec 31, 2017 | $0 | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.39M | -53.7% |
| Q1 FY2026 | Mar 31, 2026 | $2.82M | -22.4% |
| Q4 FY2025 | Dec 31, 2025 | $3.24M | +0.2% |
| Q3 FY2025 | Sep 30, 2025 | $4.57M | +59.1% |
| Q2 FY2025 | Jun 30, 2025 | $3.01M | -34.5% |
| Q1 FY2025 | Mar 31, 2025 | $3.64M | -36.1% |
| Q4 FY2024 | Dec 31, 2024 | $3.23M | -57.3% |
| Q3 FY2024 | Sep 30, 2024 | $2.87M | -68.5% |
| Q2 FY2024 | Jun 30, 2024 | $4.59M | -18.7% |
| Q1 FY2024 | Mar 31, 2024 | $5.70M | -20.5% |
| Q4 FY2023 | Dec 31, 2023 | $7.57M | -43.4% |
| Q3 FY2023 | Sep 30, 2023 | $9.11M | -55.4% |
| Q2 FY2023 | Jun 30, 2023 | $5.64M | -81.4% |
| Q1 FY2023 | Mar 31, 2023 | $7.17M | -82.6% |
| Q4 FY2022 | Dec 31, 2022 | $13.38M | -75.2% |
| Q3 FY2022 | Sep 30, 2022 | $20.41M | -67.4% |
| Q2 FY2022 | Jun 30, 2022 | $30.32M | -56.9% |
| Q1 FY2022 | Mar 31, 2022 | $41.13M | -0.7% |
| Q4 FY2021 | Dec 31, 2021 | $53.96M | -7.3% |
| Q3 FY2021 | Sep 30, 2021 | $62.50M | -6.5% |
| Q2 FY2021 | Jun 30, 2021 | $70.39M | +24.7% |
| Q1 FY2021 | Mar 31, 2021 | $41.43M | -38.3% |
| Q4 FY2020 | Dec 31, 2020 | $58.23M | -43.3% |
| Q3 FY2020 | Sep 30, 2020 | $66.84M | -42.9% |
| Q2 FY2020 | Jun 30, 2020 | $56.46M | -60.0% |
| Q1 FY2020 | Mar 31, 2020 | $67.10M | – |
| Q4 FY2019 | Dec 31, 2019 | $102.62M | – |
| Q3 FY2019 | Sep 30, 2019 | $117.03M | – |
| Q2 FY2019 | Jun 30, 2019 | $141.03M | – |
| Q1 FY2019 | Mar 31, 2019 | $0 | – |
| Q4 FY2018 | Dec 31, 2018 | $0 | – |
| Q1 FY2018 | Mar 31, 2018 | $0 | – |
| Q4 FY2017 | Dec 31, 2017 | $0 | – |
See a number that looks wrong?